RT Journal Article
SR Electronic
T1 Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.22.20025460
DO 10.1101/2020.02.22.20025460
A1 Hou, Tieying
A1 Zeng, Weiqi
A1 Yang, Minling
A1 Chen, Wenjing
A1 Ren, Lili
A1 Ai, Jingwen
A1 Wu, Ji
A1 Liao, Yalong
A1 Gou, Xuejing
A1 Li, Yongjun
A1 Wang, Xiaorui
A1 Su, Hang
A1 Gu, Bing
A1 Wang, Jianwei
A1 Xu, Teng
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.22.20025460.abstract
AB Background The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics for 2019-nCoV.Methods 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for the novel virus. The diagnostic performance of CRISPR-nCoV was assessed and also compared across three technology platforms (mNGS, RT-PCR and CRISPR)Results 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.Conclusion CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Major Science & Technology Project for Control and Prevention of Major Infectious Diseases in China; Guangdong Science and Technology Department ;Guangzhou Science, Technology and Innovation CommissionAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata unavailable